Document is current
Any future updates will be listed below
-
Authors
Schnell, Julia T.
Briviesca, Raquel Laza https://orcid.org/0000-0003-2369-567X
Kim, Taehyeung
Charbonnier, Louis-Marie
Henderson, Lauren A.
van Wijk, Femke https://orcid.org/0000-0001-8343-1356
Nigrovic, Peter A. https://orcid.org/0000-0002-2126-3702
- License Information
-
More Information
Article History
Accepted: 6 November 2024
First Online: 9 December 2024
Competing interests
: L.A.H. has received salary support from the Childhood Arthritis and Rheumatology Research Alliance (CARRA); investigator-initiated research grants from BMS; and consulting fees from Sobi, Pfizer and Adaptive Biotechnologies. F.v.W. has previously served as a speaker and/or consultant for Janssen, Johnson & Johnson and Takeda, and has received grants from Regeneron Pharmaceuticals, LEO Pharma, Sanofi, BMS, Galapagos and Takeda. P.A.N. declares consulting relationships with Alkermes, Apollo, BMS, Exo Therapeutics, Fresh Tracks Therapeutics, Merck, Novartis, Pfizer, Qiagen and Sobi; equity in Edelweiss Immune Inc.; investigator-initiated research grants from BMS and Pfizer; and authorship and editorial income from UpToDate, the American Academy of Paediatrics and Arthritis & Rheumatology. All other authors declare no competing interests.
